Repironics buys out UK distributor
This article was originally published in Clinica
US company Respironics is to acquire its UK distributor of 15 years, Profile Therapeutics. The Murrysville, Pennsylvania company agreed to buy all outstanding shares of Profile, at a price of 50.9p ($0.93) per share. The total value of the transaction is estimated at $46m. The combined annual revenues of the two companies add up to approximately $745m.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.